HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $395 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $395.
December 15, 2023 | 6:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating on Alnylam Pharmaceuticals with a $395 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and a high price target by a reputable analyst can lead to increased investor confidence and a potential short-term rise in the stock price of Alnylam Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100